14-17 June 2017, Lugano
140-P | Whole-exome-sequencing of nodal marginal zone lymphomas identifies recurrent molecular lesions in genes involved in chromatin remodelling and NOTCH signalling | Vincent Pillonel | Received |
141-P | Integrative mutational analysis of Pediatric-Type Follicular Lymphoma reveals TNFRSF14 and MAP2K1 as the most frequently mutated genes | Janine Schmidt | Received |
143-P | NOVEL MOLECULAR MARKERS FOR MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN MANTLE CELL AND FOLLICULAR LYMPHOMA: THE TARGETED LOCUS AMPLIFICATION (TLA) NGS STRATEGY | Simone Ferrero | Received |
144-P | Host Genetic Variation in the TNF and NF-?B Pathways and Prognosis in Mantle Cell Lymphoma: An Analysis of Two Studies | Yucai Wang | Received |
148-P | Kras and Ago2 interaction promotes initiation of plasmablastic lymphoma | Kevin Thai | Received |
149-P | Comprehensive epigenetic and transcriptional survey of the imprintome in normal B-cells and germinal center derived B-cell lymphomas in the framework of the MMML and ICGC MMML-Seq networks | Susanne Bens | Received |
150-P | Gene expression profiling and mutation analysis can aid treatment decision making in aggressive B cell lymphoma patients | Cathy Burton | Received |
151-P | Application of cell-of-origin subtypes determined by digital gene expression in HIV-related diffuse large B-cell lymphomas | Maria Joao Baptista | Received |
152-P | BIODLCL04: THE PROGNOSTIC ROLE OF CELL OF ORIGIN PROFILE, MYC, BCL2 AND TP53 IN UNTREATED POOR-RISK DIFFUSE LARGE B-CELL LYMPHOMA. | ANNALISA CHIAPPELLA | Received |
153-P | Prognostic significance and correlation to gene expression profile of EZH2 mutations in diffuse large B-cell lymphoma (DLBL) in two large prospective studies | Thomas Cummin | Received |
154-P | Preliminary evidence of a molecular predictor of tazemetostat response, beyond EZH2 mutation, in NHL patients via characterization of archive tumor and circulating tumor DNA | Stephen Blakemore | Received |
155-P | Array-based DNA methylome analyses of primary lymphomas of the central nervous system | Julia Vogt | Received |
159-P | Identification and characterisation of the lymphoma initiating cell (LIC) population in an ALCL mouse model | Anna Lena Illert | Received |
160-P | Oncogenic Activation of STAT3 Pathway Drives PD-L1 Expression in Natural Killer/T cell Lymphoma | Tammy Song | Received |
161-P | SAMHD1 is frequently involved in T-cell Prolymphocytic Leukemia (T-PLL) pathogenesis | Patricia Johansson | Received |
164-P | Focal skeletal 18F-FDG uptake characterizes a subset of classical Hodgkin lymphoma patients with poor outcome - A Danish-Swedish study of 209 newly diagnosed patients | Mette Abildgaard Pedersen | Received |
165-P | Histological verification of positive positron emission tomography findings during the follow-up of patients with mediastinal lymphoma: large experience on 96 patients | Pier Luigi Zinzani | Received |
166-P | SAFETY AND EFFICACY ANALYSIS OF ELDERLY PATIENTS TREATED WITHIN THE GATLA HL-05 CLINICAL TRIAL: PET adapted therapy after 3 cycles of ABVD for all stages of Hodgkin Lymphoma | Astrid Pavlovsky | Received |
167-P | Allogeneic transplantation in Hodgkins lymphoma after a failed autograft: long term outcomes and graft-versus-host disease free/relapse-free survival (GRFS) | Francesco Spina | Received |
169-P | Real life experience with brentuximab vedotin: the Italian study on 234 relapsed/refractory Hodgkins lymphoma | Pier Luigi Zinzani | Received |
170-P | A Pilot Study of Brentuximab Vedotin and AVD Chemotherapy followed by 20 Gy Involved-Site Radiotherapy in Early Stage, Unfavorable Risk Hodgkin Lymphoma | Anita Kumar | Received |
172-P | Mortality rates remain increased in young patients with classical Hodgkin lymphoma even after years in remission: Results from a Nordic Lymphoma Group Study | Jorne Biccler | Received |
173-P | Predicted Cardiac and Second Cancer Risks in Hodgkin Lymphoma Patients Treated with Advanced Proton Beam Therapy Compared to Photon Radiotherapy. | Georgios Ntentas | Received |
174-P | Cardiac disease prediction following Hodgkin lymphoma: An EORTC Lymphoma Group and GELA follow-up study | Maja Maraldo | Received |
175-P | Usefulness of N-terminal brain natriuretic peptide levels and FRESCO scale for the prediction of anthracycline-induced cardiomyotoxicity in patients with Hodgkin Lymphoma | Mariana Ferraro | Received |
178-P | Autoimmune Disease (AID) is both a Risk Factor and a Prognostic Factor Affecting Survival in Patients with B-Cell Non-Hodgkin Lymphoma (NHL) | Ora Paltiel | Received |
179-P | Microenvironmental features reflecting immunocompetence are strong outcome determinants in HIV-associated lymphoma | Maja Vase | Received |
180-P | Outcome Prediction in Diffuse Large B-cell Lymphoma Can Be Greatly Improved by Alternative Use of Clinical Information: A Nordic Lymphoma Group Study | Jorne Biccler | Received |
181-P | Simultaneous Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) at the Diagnosis has similar outcome as DLBCL | Katerina Benesova | Received |
182-P | High risk patients with diffuse large B cell lymphoma are not enrolled on clinical trials | Patrick Reagan | Received |
183-P | LONG-TERM FOLLOW-UP AFTER LOCALIZED RADIOTHERAPY IN PATIENTS WITH TRANSFORMED B-CELL LYMPHOMA TREATED WITH RITUXIMAB-CONTAINING CHEMOTHERAPY | Kenji Nozaki | Received |
184-P | Obinutuzumab-miniCHOP for the Treatment of Elderly Unfit Patients with Diffuse Large B-Cell Lymphoma. A study of the Fondazione Italiana Linfomi. | Caterina Mammi | Received |
185-P | End of treatment PET-CT predicts progression free survival in DLBCL after first-line treatment: results from the Phase III GOYA study | Madeleine Wilde | Received |
186-P | Rituximab SC and IV plus CHOP show similar efficacy and safety in the randomised MabEase study in first-line DLBCL | Madeleine Wilde | Received |
187-P | R-COMP vs. R-CHOP AS FIRST-LINE THERAPY FOR DIFFUSE LARGE B-CELL LYMPHOMA IN PATIENTS OLDER THAN 60 YEARS: RESULTS FROM A RANDOMIZED PHASE 2 STUDY FROM THE SPANISH GELTAMO GROUP | Juan-Manuel Sancho | Received |
188-P | Anthracycline Dose Intensification in Diffuse Large B-cell Lymphoma | Pengpeng Xu | Received |
189-P | Phase 2 randomized trial comparing standard RCHOP versus BRCAP as first line treatment in young patients with high-risk DLBCL. A study from Spanish Group GELTAMO | ANA MARQUEZ | Received |
191-P | Rituximab, lenalidomide, and ibrutinib alone and combined with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma | Jason Westin | Received |
194-P | Bendamustine as part of conditioning regimen for autologous stem-cell transplantation in patients with aggressive lymphomas: Final analysis of a phase 2 study from GELTAMO | Alejandro Martín | Received |
195-P | Reduced intensity (FB2) vs reduced toxicity myeloablative (FB3-4) fludarabine/busulfan based conditioning regimens for non-Hodgkin lymphoma (NHL) allografted patients. | Amandine Le Bourgeois | Received |
196-P | Double-expressor lymphomas do not have inferior outcome after autologous stem cell transplant in the first line treatment. | Marie Trnkova | Received |
197-P | Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-associated Diffuse Large B-cell Lymphomas | Michele Merli | Received |
198-P | Current therapy of secondary CNS involvement in malignant lymphoma: Data from a multicenter prospective international registry | Agnieszka Korfel | Received |
199-P | Validation of the CNS International Prognostic Index in a Large Asian Cohort Data from the Singapore Lymphoma Study Group | yuh shan Lee | Received |
202-P | Dose-dense chemoimmunotherapy and CNS prophylaxis in patients with high-risk DLBCL: a comparison of Nordic CRY-04 and CHIC studies | Sirpa Leppa | Received |
203-P | Anti-infective prophylaxis with aciclovir and cotrimoxazole significantly reduces the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy | Niels Murawski | Received |
204-P | Frequency of perforation & impact of bowel rest in aggressive non-Hodgkin lymphoma with gastrointestinal involvement: an international, multi-center retrospective study. | Collin Chin | Received |
205-P | Long Term Follow-Up and Update for Patients Enrolled in ECOG 1405 | Nadia Khan | Received |
206-P | Mantle cell lymphoma of mucosa associated lymphoid tissue: a retrospective multicenter observational study of the European Mantle Cell Lymphoma Network | Lucia Morello | Received |
208-P | R-CHOP / R-HDAC and rituximab maintenance results in high complete remission rate, minimal residual disease negativity, and excellent survival in elderly MCL patients | Pavel Klener | Received |
209-P | Maintenance rituximab improves survival in newly diagnosed mantle cell lymphoma patients: analysis of the Czech Lymphoma Study Group | Ale Obr | Received |
210-P | Rituximab Maintenance after Nordic Protocol (R-MaxiCHOP/HD-AraC/ASCT) Significantly Prolongs Survival in Young Mantle Cell Lymphoma Patients | Pavel Klener | Received |
211-P | SAKK 36/13 - Ibrutinib and bortezomib followed by ibrutinib maintenance in patients with relapsed and refractory mantle cell lymphoma: Phase I report of a Phase I/II trial | Urban Novak | Received |
212-P | Phase I/II clinical trial of a tumor cell vaccine followed by vaccine-primed lymphocyte infusion for patients with Mantle Cell Lymphoma | Matthew Frank | Received |
213-P | Obinutuzumab plus Ibrutinib in relapse/refractory mantle cell lymphoma patients: first results of the Oasis phase I trial. | STEVEN LE GOUILL | Received |
214-P | Rituximab maintenance after autologous stem cell transplantation in patients with mantle cell lymphoma, final result of the LyMa trial conducted on behalf the LYSA group | Steven Le Gouill | Received |
217-P | Progression-free survival following lenalidomide-based treatment is significantly longer in extragastric than in gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) | Barbara Kiesewetter | Received |
219-P | Treatment with combination of lenalidomide and rituximab achieves durable responses in a long term follow up of patients with indolent non-hodgkins lymphoma | Maria Chaudhry | Received |
220-P | Minimal residual disease and outcomes in relapsed/refractory follicular lymphoma (FL) in the Phase III GADOLIN trial of obinutuzumab and bendamustine vs bendamustine | Madeleine Wilde | Received |
221-P | R-CP chemoimmunotherapy in patients with IgM paraproteinaemic neuropathy produces improvements in functional, electrophysiological and serological outcomes. | Andrew Duncombe | Received |
222-P | Bendamustine-rituximab (BR) versus R-CHOP as upfront therapy for indolent B-cell lymphomas: a comparative, population-based analysis | Adam Olszewski | Received |
223-P | A DOUBLE-BLIND, RANDOMIZED PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT-P10 TO RITUXIMAB IN COMBINATION WITH CVP IN PATIENTS WITH ADVANCED-STAGE FOLLICULAR LYMPHOMA | EunJin Choi | Received |
224-P | Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation at rituximab era | PIERRE SESQUES | Received |
225-P | Autologous Stem Cell Transplantation may potentially abrogate the negative prognostic effect of early relapse after chemo or inmunochemotherapy in Follicular Lymphoma | Ana Jiménez Ubieto | Received |
226-P | Autologous transplantation improves survival in patients with follicular lymphoma experiencing early therapy failure after frontline chemoimmunotherapy: A NLCS and CIBMTR analysis | CARLA CASULO | Received |
227-P | Minimal residual disease (MRD) in early stage follicular lymphoma can predict prognosis and drive rituximab treatment after radiotherapy | ALESSANDRO PULSONI | Received |
228-P | Low Grade B-cell Non-Hodgkin Lymphomas involving the Central Nervous System: An Analysis from the National Cancer Database | Priyanka Pophali | Received |
230-P | Patients with follicular lymphoma (FL) in maintained complete response (CR) at 30 months show a survival similar to a sex- and age-matched Spanish general population | Laura Magnano Mayer | Received |
231-P | POD24 and CR30 are promising surrogate endpoints for assessing the outcome of patients with advanced stage Follicular Lymphoma enrolled in the FOLL05 trial by FIL. | Martina Manni | Received |
232-P | Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed Follicular lymphoma in the Rituximab era | Connie Batlevi | Received |
233-P | Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma | Jacob Soumerai | Received |
234-P | Statin use and prognosis in 12,865 non-Hodgkin lymphoma patients treated in the Rituximab-era | Elsa Brnvall | Received |
235-P | Ibrutinib Increases the Systemic Exposure of Rituximab: Pharmacokinetic Results from the HELIOS Trial | Laurie Orloski | Received |
239-P | Outcomes with Bruton Tyrosine Kinase Inhibition in relapsed / refractory chronic lymphocytic leukemia / small lymphocytic lymphoma after progression on venetoclax | Mary Ann Anderson | Received |
240-P | Outcomes of patients post ibrutinib treatment for relapsed / Refractory CLL: A UK and Ireland analysis | George Follows | Received |
241-P | Ibrutinib For Relapsed / Refractory CLL: An update of the UK And Ireland Analysis Of Outcomes In 315 Patients | George Follows | Received |
244-P | Outcome of patients with relapsed and refractory peripheral T cell lymphoma intended for stem cell transplant | Stephen Parkin | Received |
245-P | A multi-center study of GLIDE chemotherapy consolidated with autologous stem cell transplantation for newly diagnosed stage IV and relapsed extranodal natural killer/T-cell lymphoma patients | Jie Ji | Received |
246-P | Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for Patients with Relapsed/Refractory Systemic Anaplastic Large Cell Lymphoma (R/R sALCL). A Retrospective Analysis of the Lymphoma Working Party-EBMT. | Eva Domingo Domenech | Received |
247-P | Risk stratification based on NCCN-IPI at the time of diagnosis in combination with post-treatment PET-CT scan for the treatment of nodal peripheral T-cell lymphoma | Ho-Young Yhim | Received |
252-P | Prognostic factors in patients with relapsed or refractory systemic anaplastic large T-cell lymphoma (ALCL) receiving brentuximab vedotin and outcome after treatment failure. | Yasuhiro Oki | Received |
253-P | Case Match Control Analysis of PROPEL Reveals a Survival Advantage for Patients with Relapsed PTCL Receiving Pralatrexate: A Novel Approach to Benchmark Drugs in Rare Diseases | Owen OConnor | Received |
254-P | A Post-marketing Surveillance Study of 703 Patients Treated with Chidamide for Peripheral T-cell Lymphoma (PTCL) in China HDAC Study Group of Union for China Lymphoma Investigators(UCLI) | Jian Chen | Received |
255-P | Preliminary results from an open-label, phase II study of tipifarnib in relapsed or refractory peripheral T-cell lymphoma. | Catherine Scholz | Received |
256-P | Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: Interim results of postmarketing all-case surveillance | Satoshi Yurimoto | Received |
257-P | Targeting the T-cell receptor -constant domain for immunotherapy of T-cell malignancies | Paul Maciocia | Received |
258-P | Development of novel, non-toxic rifamycins that reverse drug resistance in diffuse large B-cell lymphoma (DLBCL) | Steve Maxwell | Received |
260-P | Dual inhibition of EZH2 and HDAC is synergistic in EZH2 dysregulated lymphomas | Jennifer Lue | Received |
261-P | STRO-001, A NOVEL ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC) FOR TREATMENT OF B-CELL NON-HODGKINS LYMPHOMAS (NHL) | Arturo Molina | Received |
263-P | Copanlisib in combination with anti-PD-1 induces regression in animal tumor models insensitive or resistant to the monotherapies of PI3K and checkpoint inhibitors | Ningshu Liu | Received |
264-P | PD--1 immune checkpoint blockade improves anti--CD20 based immunotherapy in follicular lymphoma | cédric rossi | Received |
265-P | Characterization and integration of mantle cell lymphoma microenvironments are determinant for the development of rational targeted therapies | David Chiron | Received |
266-P | Effective therapy by anti-CD81 against B cell lymphomas engages both direct and indirect immune mechanisms | Shoshana Levy | Received |
268-P | Expression of LAG-3 defines exhaustion of intratumoral PD-1 T cells and correlates with poor outcome in follicular lymphoma | Zhizhang Yang | Received |
271-P | A phase I study of chimeric antigen receptormodified T cells directed against CD19 in patients with relapsed or refractoryCD19() B cell Lymphomas: interim analysis | Zhitao Ying | Received |
273-P | Safety and Clinical Activity of RP6530, a Dual PI3Kd/? Inhibitor, in Patients with advanced Hematologic Malignancies: Analysis of a Phase 1 Multi-center Study | Prajak Barde | Received |
278-P | Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-cell Lymphoma: Phase I/II Results | Jason Westin | Received |
280-P | The Immunologic Doublet of Lenalidomide Plus Obinutuzumab is Highly Active in Relapsed/Refractory Follicular Lymphoma, Results of a Phase I/II Study | Nathan Fowler | Received |
284-P | Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory FL or DLBCL: updated results of a phase 1b/2 study | Anne Nunn | Received |
285-P | YourTreatmentChoices: Fast Access to Trials Programme | George Xinarianos | Received |
286-P | Increasing cross-referral and recruitment to clinical trials: a new APProach | Judith Trotman | Received |
287-P | Oral Azacytidine (AZA) and Romidepsin (R) Reveals Promising Activity in Patients with Relapsed or Refractory (R/R) Peripheral T-cell Lymphoma (PTCL) | Owen OConnor | Received |
288-P | CD70 expression in Cutaneous T cell lymphoma (CTCL) patients and mechanisms of action of ARGX-110 in skin: histopathological and clinical data | Anna Hultberg | Received |
14-17 June 2017, Lugano
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|